FibroGen to Report Second Quarter 2022 Financial Results

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) will release its Q2 2022 financial results on August 8 after market close. The company will also hold a conference call at 5:00 p.m. ET to discuss its corporate and financial performance with investors. FibroGen is known for developing innovative therapeutics, including pamrevlumab for idiopathic pulmonary fibrosis, and roxadustat for various types of anemia. They have recently expanded their R&D portfolio into immuno-oncology and autoimmune therapies.

Positive

• FibroGen is progressing its dual pipeline with pamrevlumab and roxadustat, addressing significant medical needs.
• Recent expansion into immuno-oncology and autoimmune therapy could enhance growth opportunities.

Negative

• None.

SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay).

About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.

Contacts: FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.978.1434
mtung@fibrogen.com

Media:
Meichiel Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com

 

FAQ

When will FibroGen announce its Q2 2022 financial results?

FibroGen will announce its Q2 2022 financial results on August 8 after market close.

What is the purpose of FibroGen's conference call on August 8?

The conference call will detail FibroGen's corporate and financial performance.

What key products is FibroGen developing?

FibroGen is developing pamrevlumab for idiopathic pulmonary fibrosis and roxadustat for anemia.

How can I access the FibroGen conference call?

You can access the conference call via the Investor Relations page on FibroGen's website or through a registration link for phone access.

What new areas is FibroGen exploring in its research?

FibroGen has expanded its R&D portfolio to include immuno-oncology and autoimmune therapies.